Back to top
more

Eli Lilly (LLY)

(Delayed Data from NYSE)

$891.07 USD

891.07
1,751,171

+6.59 (0.75%)

Updated Oct 2, 2024 04:00 PM ET

After-Market: $891.10 +0.03 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 17% (44 out of 252)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Teva Gains Positive CHMP Opinion for Migraine Drug Ajovy

Teva (TEVA) receives positive opinion from the Committee for Medicinal Products for Human Use (CHMP), advocating a marketing approval for its new migraine medicine, Ajovy.

Novo Nordisk (NVO) Q4 Earnings Miss Estimates, Revenues Beat

Novo Nordisk (NVO) fourth-quarter 2018 results mainly benefit from strong performance by Ozempic.

Lilly (LLY) Hits 52-Week High, Can the Run Continue?

Lilly (LLY) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Pharma Stock Roundup: Q4 Earnings, Pipeline Updates at PFE, RHHBY

Pfizer (PFE), Allergan (AGN), AbbVie (ABBV) and Novartis (NVS) report Q4 results.

J&J's Erleada Meets Both Primary Endpoints in Late-Stage Study

Johnson & Johnson's (JNJ) Erleada improves survival in metastatic castration-sensitive prostate cancer study.

Eli Lilly (LLY) Q4 Earnings Coming Up: What's in the Cards?

Eli Lilly and Company's (LLY) new drugs like Trulicity, Taltz and Jardiance are performing well. Let's see if these along with its older products lead the company to an earnings beat.

Lilly/Pfizer's Osteoarthritis Pain Drug Succeeds in 2nd Study

Eli Lilly (LLY) and Pfizer announce that their investigational pain candidate, tanezumab, achieves significant reduction in pain in osteoarthritis patients in second late-stage study.

Dr. Reddy's (RDY) to Report Q3 Earnings: What's in Store?

Dr. Reddy's has launched few generics which should add to revenues of the company when the company releases its third-quarter fiscal 2019 results.

Allergan Hikes Quarterly Dividend by 2.8% Ahead of Q4 Results

Allergan (AGN) approves a cash dividend of 74 cents for 2019, a 2.8% raise from the previous payout of 72 cents.

The Zacks Analyst Blog Highlights: J&J, Bristol-Myers, Lilly, AbbVie and Merck

The Zacks Analyst Blog Highlights: J&J, Bristol-Myers, Lilly, AbbVie and Merck

Pharma Stock Roundup: JNJ & BMY's Q4 Earnings, Study Failures at LLY & ABBV

J&J (JNJ) and Bristol-Myers (BMY) kick off earnings for pharma sector. Lilly (LLY) and AbbVie (ABBV) announce failure of late-stage studies.

Merck KGaA Gives Vertex Rights to Two Gene-Editing Compounds

Merck KGaA (MKGAF) inks an exclusive licensing agreement with Vertex for two DNA-dependent protein kinase inhibitors in the field of gene editing for six specific genetic disease indications.

Sanghamitra Saha headshot

What's Behind the Biotech ETF Rally to Start 2019?

Biotech ETFs have been riding on the wave of mergers and acquisitions as well as drug approvals.

Bristol-Myers (BMY) Beats Q4 Earnings, Withdraws Opdivo sBLA

Bristol-Myers (BMY) beats earnings estimates in the fourth quarter but misses sales expectation by a slight margin. Eliquis and Opdivo continue to record solid sales.

The Zacks Analyst Blog Highlights: Archer Daniels Midland, Molina Healthcare, Eli Lilly, Spark Energy and Lamb Weston

The Zacks Analyst Blog Highlights: Archer Daniels Midland, Molina Healthcare, Eli Lilly, Spark Energy and Lamb Weston

Sanofi's (SNY) Influenza Vaccine Gets FDA Approval for Kids

Sanofi's (SNY) influenza vaccine, Fluzone Quadrivalent (0.5mL dose), gains an FDA nod for treating children in six to 35-month age group.

5 Best Biotech Bets Likely to Outperform Estimates in Q4

Let us take a look at five promising biotech stocks for the fourth quarter of 2018.

Swarup Gupta headshot

6 Stocks to Prepare for a Global Economic Slowdown

A slowdown in Europe and the ongoing trade conflicts have been cited as the major reasons for the IMF's projection cuts.

J&J's (JNJ) Q4 Earnings Beat, 2019 Sales Forecast Soft

J&J (JNJ) beats estimates for both earnings and sales in the fourth quarter of 2018, leading to an increase in shares in pre-market trading. 2019 sales guidance falls short of expectations.

Company News For Jan 22, 2019

Companies In The News Are: TIF,LLY,KSU,JBHT

Lilly Stops Lartruvo Promotion as Confirmatory Study Fails

Eli Lilly's (LLY) Lartruvo combo is unable to demonstrate the clinical benefit for the primary endpoint of OS rate in a phase III study related to treating patients with metastatic soft tissue sarcoma.

Pharma Stock Roundup: Regulatory Updates in Focus at PFE, BMY, RHHBY, SNY

Pfizer's (PFE) tafamidis application gets FDA's priority review. Regulatory updates for Roche's (RHHBY) and Bristol-Myers'(BMY) cancer combination drugs in focus.

Here is Why Growth Investors Should Buy Lilly (LLY) Now

Lilly (LLY) possesses solid growth attributes, which could help it handily outperform the market.

Madhu Goel headshot

Pacira's Study on Exparel Label Expansion Meets Endpoints

Pacira's (PCRX) phase IV study of its lead drug Exparel in patients undergoing Cesarean section achieves primary endpoint.